(Date:12/3/2009)... , HOUSTON, Dec. 3 JourneyL...pdated its facility to offer patients a second sur... with the LAP-BAND® System that it currentl... at the facility was performed by surgeon partner,...e patient is reported as doing well. ,, The Ver...
(Date:12/3/2009)..., PHILADELPHIA, Dec. 3 /PRNewswire-FirstCall/ -...l specialty biopharmaceutical company, today annou... market withdrawal of one lot of the Attention-Def...® . Shire is taking this action because some ...not meet their release liner removal specification...
(Date:12/3/2009)... , NEW DELHI, India, Dec. 3 /PRNewswi...ience Officer at Shenzhen Beike Biotechnology Co. ...conference on High-Risk Diabetic,Foot Care in New ...leading,stem cell research and regenerative medici...y the Indian Podiatry Association (IPA), aimed,to ...
(Date:12/2/2009)... , NEW YORK, Dec. 2 Report...port is available in its catalogue: ,, Carbond..., http://www.reportlinker.com/p0164368/Carbond...ml ,, Incubators are the most critical equipm...ch, and other applications for providing a control...
Breaking Biology Technology:JourneyLite of Houston Now Offering Sleeve Gastrectomy 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4...Call/ - Dragon Pharmaceutical Inc.,(TSX: DDD; OTCB...results,for the second quarter ended June 30, 2007...les increased 48% to $20.55 million from $13.89 mi...sed 19% as compared to the first quarter 2007... $3.98 million and 19.36% from $2.39 million ...
... XTL,Biopharmaceuticals Ltd. (NASDAQ: XTLB ; LSE:...ged in the acquisition, development and,commercial... medical needs,particularly neuropathic pain and h...for the six months ended June 30, 2007. At June 3...d short-term,bank deposits of $12.6 million, compa...
...peutics,Inc. (Nasdaq: CVTX ) announced today that... College of Cardiology Foundation and the American...sue of Circulation, state that,"ranolazine may be ...TEMI." Ranexa(R) (ranolazine extended-release tab...gina in patients who have not achieved an adequate...
Other Biology Technology:Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007 2Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007 3XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 2XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 3XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 4XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 5XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 6XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 7XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 8XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 9XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 10XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 11XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 12XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 13XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 14Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI) 2... On November 1415, over 40 scientists will convene...llbrook, New York to discuss the future of biofuel...l include some of our nations leading biofuel expe...sity), Charles Hall (SUNY-ESF), and G. Philip Robe...l have been touted as sustainable alternatives to ...
... For more than 40 years, researchers have suspect...ly flush sodium out of the body and could be harne...s for high blood pressure, or hypertension. Curren...us side effects because they also reduce potassium...mpson Institute for Plant Research (BTI) have used...
... MOSCOW/POST FALLS, Idaho University of Idaho re...ounds to develop more effective defenses against S...hogens. , One of the goals of that effort is to...on of strains resistant to the antibiotic methicil...ylococcus aureus, or MRSA. , Breakthrough detecti...
Other Biology News:Can plant-based ethanol save us from our fossil fuel addiction? 2Researchers' discovery may lead to hypertension treatment 2Developing kryptonite for Superbug 2Developing kryptonite for Superbug 3Developing kryptonite for Superbug 4Developing kryptonite for Superbug 5Rat Anti-Mouse Serpin F1 / PEDF Monoclonal Antibody, Unconjugated, Clone 199315 from R&D Systems
Rat Anti-HP1 gamma Monoclonal Antibody, Unconjugated, Clone MAC385 from ABR-Affinity BioReagents
Prostaglandin E2 Luminex Standard from Cayman Chemical
Eppendorf tube holder, for Tube rack 175 x 12 mm from GE Healthcare, formerly Amersham Biosciences
Biology Products: